EUVIMEDEUVIMED entdecken
Open Access · CC BY 4.0

Predictive Value of Neutrophil‐to‐Lymphocyte Ratio for Immune Checkpoint Inhibitor‐Related Myocarditis Among Patients Treated for Non‐Small‐Cell Lung Cancer

Jian Xue, Chuanbin Liu, Jun Shao, Li Wang, Yating Han, Jing Wang iD, Jinda Wang

Cancer Innovation · 2025-04 · 4 (2)

DOI: 10.1002/cai2.163 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Cancer Innovation, online erschienen am 20.02.2025. Verfasst von Jian Xue und 6 weiteren Autor:innen. Beteiligte Einrichtung: Senior Department of Cardiology The Sixth Medical Center of Chinese PLA General Hospital Beijing China. Die Arbeit wurde bisher 14-mal zitiert (Crossref) und nennt 37 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0).

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Background

The predictive value of the neutrophil‐to‐lymphocyte ratio (NLR) for immune checkpoint inhibitors (ICIs) in various tumors remains uncertain despite its use in forecasting the effectiveness of immunotherapy. The purpose of our research was to determine the prognostic significance of NLR for immune checkpoint inhibitor‐related myocarditis in non‐small‐cell lung cancer (NSCLC) patients.

Methods

We enrolled and monitored patients with NSCLC who received ICI therapy at the Fifth Medical Center of Chinese PLA General Hospital between January 1, 2018, and February 20, 2021. NLR was determined before and soon after each cycle of ICIs. All participants in this study were periodically examined for troponin and brain natriuretic peptide (BNP), and an electrocardiogram (ECG) and echocardiography were done. Cox's proportional hazards regression model and receiver operating characteristic (ROC) were used to assess the predictive value for ICI‐related myocarditis.

Results

A total of 146 patients received ICI treatment and completed a follow‐up. Of these, 17 patients (11.64%) developed ICI‐related myocarditis that met the diagnostic criteria. The initial cycle revealed that the NLR was a reliable predictor of potential myocarditis related to ICIs, with an area under the curve (AUC) of 0.833 and a 95% confidence interval (CI) of 0.721–0.945. Following the initial round of ICI treatment, an NLR elevation (NLR ≥ 3.25) appeared to be the most significant standalone indicator of ICI‐related myocarditis (HR: 11.094; 95% CI: 3.186–38.631; p < 0.001).

Conclusions

Our study confirmed that NLR elevation in the early phase after ICI treatment of NSCLC is a reliable predictive factor of ICI‐related myocarditis. Regular and frequent cardiac monitoring may help to avoid the occurrence of severe and fatal cases.

Schlagwörter

Stichwörter der Autor:innen

biomarkersimmune checkpoint inhibitors‐related myocarditisimmunotherapyneutrophil‐to‐lymphocyte rationon‐small‐cell lung cancer

Autor:innen und Institutionen

  • Senior Department of Cardiology The Sixth Medical Center of Chinese PLA General Hospital Beijing China.
  • Western Medical Branch of Chinese PLA General Hospital Beijing China.
  • Department of Emergency The First Medical Center of Chinese PLA General Hospital Beijing China.
  • Department of General Surgery The First Medical Center of Chinese PLA General Hospital Beijing China.

ORCID-Profile: Jing Wang

Zitieren

APA

Xue, J., Liu, C., Shao, J., Wang, L., Han, Y., Wang, J., & Wang, J. (2025). Predictive Value of Neutrophil‐to‐Lymphocyte Ratio for Immune Checkpoint Inhibitor‐Related Myocarditis Among Patients Treated for Non‐Small‐Cell Lung Cancer. Cancer Innovation, 4(2). https://doi.org/10.1002/cai2.163

Vancouver

Xue J, Liu C, Shao J, Wang L, Han Y, Wang J, et al. Predictive Value of Neutrophil‐to‐Lymphocyte Ratio for Immune Checkpoint Inhibitor‐Related Myocarditis Among Patients Treated for Non‐Small‐Cell Lung Cancer. Cancer Innovation. 2025;4(2). doi:10.1002/cai2.163

BibTeX
@article{Xue2025,
  author = {Xue, Jian and Liu, Chuanbin and Shao, Jun and Wang, Li and Han, Yating and Wang, Jing and Wang, Jinda},
  title = {Predictive Value of Neutrophil‐to‐Lymphocyte Ratio for Immune Checkpoint Inhibitor‐Related Myocarditis Among Patients Treated for Non‐Small‐Cell Lung Cancer},
  journal = {Cancer Innovation},
  year = {2025},
  volume = {4},
  number = {2},
  doi = {10.1002/cai2.163}
}
Kostenlos starten →